SciSparc Ltd. (Nasdaq: SPRC) and Clearmind Medicine Inc. (Nasdaq: CMND) have filed a new international patent application for a novel treatment targeting anorexia, bulimia, and other eating disorders.

The application covers the use of 3-Methylmethcathinone (3-MMC) combined with SciSparc’s Palmitoylethanolamide (PEA), aiming to address complex biological and psychological factors involved in eating disorders.

Eating disorders affect an estimated 70 million people globally, with prevalence rates rising significantly over the past two decades.

Last month, SciSparc and Clearmind also announced the publication of a patent application in South Korea covering a combination of Clearmind’s MEAI compound and SciSparc’s PEA for the treatment of cocaine addiction, based on preclinical studies showing a reduction in drug-seeking behavior without impairing natural reward responses.

SciSparc is a clinical-stage biotechnology company with four drug candidates in clinical trials targeting Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer’s Disease and Agitation, and Autism Spectrum Disorder, as well as two pre-clinical programs for Status Epilepticus and Chronic Pain.

Clearmind Medicine focuses on developing revolutionary psychedelics for treating addiction and mental health, with programs aimed at conditions like alcohol use disorder, binge eating, and depression.

Both companies are members of the PRISM Emerging Psychedelics Index.